Evidence map›Paper›PMID 41846122›Full record

ReviewNeuroImage. Clinical2026

Ultra-high field brain MRI for functional neurological disorder: opportunities and challenges.

Sverre Myren, Johannes Jungilligens, Ibai Diez, Erlend Bøen, Torbjørn Elvsåshagen, Birte Forstmann, Maryam Ziaei, Thanh P Doan

Abstract readReview
In one paragraph

Review in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sverre MyrenDepartment of Neurology, Ålesund Hospital, Ålesund, Norway; Clinical Brain Systems (CBS) Group, Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Department of Health Sciences Ålesund, Norwegian University of Science and Technology (NTNU), Ålesund, Norway. Electronic address: sverre.myren@ntnu.no.
Johannes JungilligensDepartment of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany. Electronic address: johannes.jungilligens@rub.de.
Ibai DiezCenter for Inflammation Imaging, Mass General Brigham, Harvard Medical School, Boston, MA, USA; Computational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque - Basque Foundation for Science, Bilbao, Spain. Electronic address: idiezpalacio@mgh.harvard.edu.
Erlend BøenSection of Psychosomatic Medicine, Oslo University Hospital, Oslo, Norway. Electronic address: erboen@ous-hf.no.
Torbjørn ElvsåshagenDepartment of Behavioural Medicine, Institute of Basic Clinical Sciences, University of Oslo, Oslo, Norway; Department of Neurology, Oslo University Hospital, Oslo, Norway; Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. Electronic address: torbjorn.elvsashagen@medisin.uio.no.
Birte ForstmannDepartment of Psychology, the University of Amsterdam, Amsterdam, the Netherlands. Electronic address: b.u.forstmann@uva.nl.
Maryam ZiaeiKavli Institute for Systems Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Electronic address: maryam.ziaei@ntnu.no.
Thanh P DoanClinical Brain Systems (CBS) Group, Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, St. Olav's University Hospital, Trondheim, Norway. Electronic address: thanh.p.doan@ntnu.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functional neurological disorder (FND) is a common condition with debilitating neurological symptoms emerging from brain network alterations; yet, neuroimaging findings are often of unclear neurobiological significance. Contemporary mechanistic accounts indicate disturbances in hierarchical brain processing involving arousal, interoception, salience attribution, affective-motor integration, and self-agency. The findings of abnormal brain function with only partially consistent neuroimaging abnormalities imply that relevant pathology may occur below the resolution or contrast capabilities of conventional clinical MRI. Ultra-high field MRI (UHF, 7T and above) provides substantially improved spatial resolution, contrast sensitivity, and physiological specificity needed to interrogate microcircuit-, mesoscale-, and neurochemical-level mechanisms. We review how UHF-enhanced structural, diffusion, functional, and spectroscopic techniques can address long-standing mechanistic questions in FND. Selected targets that operate at different spatial scales are used to illustrate how UHF MRI can resolve features that are either inaccessible or not fully reliable at standard magnetic field strengths (1.5-3T). To synthesize these advances, we propose a biophysical multimodal MRI framework that integrates quantitative MRI, diffusion MRI, functional MRI, and MR spectroscopy to derive biologically interpretable markers spanning microstructure, white matter architecture, circuit dynamics, and neurometabolic domains. This approach aligns with contemporary computational and neurobiological models of FND and offers a scalable roadmap for future research. Together, UHF MRI and biophysically grounded multimodal imaging can enable a new generation of mechanistic studies in FND, with potential implications for diagnosis, subtype stratification, and biomarker development.

Indexed as

BrainMagnetic Resonance ImagingNervous System DiseasesNeuroimagingHumans7T MRIBiophysical multimodal MRIFNDFunctional neurological disorderQuantitative MRIUltra-high field MRI

Identifiers

PMID41846122
PMCPMC13010964

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.